Rani Therapeutics Holdings (RANI) Income from Continuing Operations (2020 - 2026)

Rani Therapeutics Holdings has reported Income from Continuing Operations for 7 years, with the latest figure at -$8.4 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations rose 24.97% year-over-year to -$8.4 million in Q2 2026; TTM through Jun 2026 was -$32.8 million, a 37.32% increase from a year earlier, with the FY2025 full-year figure at -$40.4 million, up 28.65% from the prior year.
• Income from Continuing Operations was -$8.4 million for Q2 2026 at Rani Therapeutics Holdings, down from -$8.0 million in the prior quarter.
• The five-year high for Income from Continuing Operations was -$7.9 million in Q3 2025, with the low at -$18.7 million in Q2 2023.
• Average Income from Continuing Operations over 5 years is -$13.6 million, with a median of -$13.9 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 191.08% in 2022, then jumped 45.95% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$17.4 million in 2022, then rose by 19.09% to -$14.1 million in 2023, then decreased by 11.86% to -$15.7 million in 2024, then surged by 45.95% to -$8.5 million in 2025, then climbed by 0.91% to -$8.4 million in 2026.
• The last three Income from Continuing Operations figures came in at -$8.4 million (Q2 2026), -$8.0 million (Q1 2026), and -$8.5 million (Q4 2025), per Business Quant data.